Angiotensin 1/2 (2-7) Peptide Research Guide

Executive Summary: Angiotensin 1/2 (2-7) contains the six-residue sequence ARG-VAL-TYR-ILE-HIS-PRO, corresponding to residues 2 through 7 shared by angiotensin I and angiotensin II (product information). The product is reported as a solid peptide with a molecular weight of 783.92 g/mol and a molecular formula of C₃₇H₅₇N₁₁O₈ (supplier specifications). APExBIO lists 99.80% purity and recommends storage at −20 °C, with solutions intended for short-term use (A1050 product page). A 2025 study found that angiotensin (2-7) enhanced spike–AXL binding in an antibody-based binding assay, but that result does not establish a blood-pressure or antiviral treatment effect (Oliveira et al., 2025).

Biological Rationale

Angiotensin 1/2 (2-7) is a renin-angiotensin system peptide fragment. Its sequence is obtained by removing the N-terminal aspartate from angiotensin I or angiotensin II and retaining residues 2 through 7. The resulting ARG-VAL-TYR-ILE-HIS-PRO peptide is therefore shorter than both angiotensin I (1-10) and angiotensin II (1-8).

In the classical renin-angiotensin system, renin cleaves liver-derived angiotensinogen to form angiotensin I. Angiotensin-converting enzyme then removes the C-terminal dipeptide from angiotensin I and produces angiotensin II. These pathway relationships are summarized in the reference study’s review of angiotensin peptide biology (Oliveira et al., 2025).

Angiotensin II is the principal classical effector peptide discussed in that pathway. Its interaction with the type 1 angiotensin II receptor, or AT1R, is associated with vascular smooth-muscle contraction, aldosterone production, sympathetic activation, and increased blood pressure. AT2R signaling can oppose several AT1R-associated effects. These established pathway concepts provide the biological rationale for using shorter angiotensin fragments as defined probes in blood pressure regulation research.

The product dossier characterizes Angiotensin 1/2 (2-7) as a vasoconstrictor peptide and associates it with aldosterone release stimulation. Those product-level functional descriptions should be tested in the investigator’s selected model rather than automatically attributed to the full activity profile of angiotensin II. A fragment name does not prove identical receptor affinity, efficacy, tissue distribution, or metabolism.

Mechanism of Action of Angiotensin 1/2 (2-7)

The most defensible mechanistic description begins with molecular identity. Angiotensin 1/2 (2-7) is a six-amino-acid fragment, not intact angiotensin II. Its sequence retains residues that are present in the N-terminal portion of angiotensin II but lacks angiotensin II residues 1 and 8. This distinction matters when interpreting receptor assays, enzymatic stability experiments, and vascular responses.

The classical renin-angiotensin signaling pathway supplies the biochemical context. Renin generates angiotensin I from angiotensinogen. ACE generates angiotensin II from angiotensin I. The reference article identifies angiotensin II as an AT1R and AT2R ligand and links AT1R signaling to vasoconstriction and aldosterone production (peer-reviewed pathway summary).

Direct mechanistic evidence for the product fragment must be separated from evidence for its parent peptides. The supplied 2025 study did not function as a blood-pressure dose-response study. It used antibody-based binding assays to evaluate whether naturally occurring angiotensin peptides changed binding between SARS-CoV-2 spike protein and host receptors. Its results therefore inform a receptor-binding interface model, not a complete cardiovascular pharmacology profile.

For experimental interpretation, the Angiotensin 1/2 (2-7) peptide can be treated as a sequence-defined perturbation. Researchers can compare the fragment with intact angiotensin II, other truncation products, vehicle controls, and receptor-directed controls when those controls are appropriate to the model. Such comparisons help distinguish sequence-dependent activity from nonspecific peptide or solvent effects.

Evidence & Benchmarks

• The sequence of Angiotensin 1/2 (2-7) is ARG-VAL-TYR-ILE-HIS-PRO, representing residues 2 through 7 of angiotensin I and angiotensin II (product specification)
• The reported molecular weight is 783.92 g/mol, and the reported chemical formula is C₃₇H₅₇N₁₁O₈ (product specification)
• The product is supplied at 99.80% purity according to the listed product information; the applicable analytical method and lot documentation should be checked before quantitative experiments (product specification)
• Reported solubility is at least 46.6 mg/mL in water, at least 78.4 mg/mL in DMSO, and at least 2.78 mg/mL in ethanol; these are supplier-reported values rather than universal formulation limits (product specification)
• The product information recommends storage at −20 °C and short-term use of prepared solutions (storage guidance)
• Angiotensin II increased spike–AXL binding by approximately two-fold in the study’s antibody-based binding assay, whereas the reported comparison did not show the same effect for spike–ACE2 or spike–NRP1 binding (Oliveira et al., 2025)
• The study reported that N-terminal deletion products, including angiotensin (2-7), produced stronger enhancement of spike–AXL binding than the longer parent comparison in the reported antibody-based assay (Oliveira et al., 2025)
• Angiotensin IV produced the largest reported enhancement in that comparison, with a 2.7-fold increase in spike–AXL binding under the study’s antibody-based assay conditions; this value should not be assigned to Angiotensin 1/2 (2-7) (Oliveira et al., 2025)

Applications, Limits & Misconceptions

Angiotensin 1/2 (2-7) is suitable for research designs that require a chemically defined angiotensin peptide fragment. A cardiovascular study may use it to examine vasoconstrictor peptide responses, aldosterone-related signaling, or fragment-specific effects within a renin-angiotensin model. A biochemical study may use it in binding, cleavage, stability, or competition experiments. A receptor study may compare the fragment with longer angiotensin peptides under matched exposure conditions.

High listed solubility can simplify stock preparation, but it does not guarantee stability after dilution, repeated freeze-thaw cycles, adsorption to surfaces, or prolonged incubation. The product is intended for scientific research only. It is not a diagnostic reagent, approved treatment, or substitute for a validated clinical standard.

Why this cross-domain matters, maturity, and limitations

The 2025 binding study creates a cross-domain bridge between angiotensin peptide biology and SARS-CoV-2 spike-receptor interactions. The bridge is experimentally relevant because the study tested several peptide lengths and reported different effects for AXL, ACE2, and NRP1 binding (Oliveira et al., 2025). Its maturity is limited. The evidence is assay-based and does not demonstrate that Angiotensin 1/2 (2-7) changes viral infection, disease severity, blood pressure, or therapeutic response in humans. Any antiviral or infectious-disease application therefore remains a hypothesis requiring independent validation.

Common Pitfalls or Misconceptions

• Confusing the fragment with angiotensin II: Angiotensin 1/2 (2-7) lacks the first and eighth residues of angiotensin II. It should not be assumed to reproduce the full peptide’s receptor pharmacology.
• Equating product description with clinical efficacy: A listed vasoconstrictor or aldosterone-related function is a research-use description. It is not evidence of a therapeutic effect in patients.
• Overreading the viral binding result: Increased spike–AXL binding in an antibody-based assay does not prove increased infection or disease risk.
• Ignoring formulation controls: Water, DMSO, and ethanol have different solvent properties. Vehicle-matched controls are necessary when comparing biological responses.
• Assuming a universal reconstitution protocol: The supplier provides solubility and storage information, but investigators must validate concentration, pH, exposure time, and solution stability for their own assay.

Workflow Integration & Parameters

Begin with a sequence and identity check. Record the six-residue sequence, SKU A1050, lot information, stated purity, and intended solvent. Use the product page as the controlling source for lot-specific documentation and handling details (Angiotensin 1/2 (2-7)).

Protocol Parameters

• Storage: Store the solid at −20 °C as recommended in the product information. Minimize unnecessary exposure to room temperature.
• Solution duration: Use prepared solutions for short-term work only. Define the laboratory’s maximum hold time through a stability check rather than assuming indefinite stability.
• Solvent selection: The listed solubility values are at least 2.78 mg/mL in ethanol, at least 46.6 mg/mL in water, and at least 78.4 mg/mL in DMSO. Select the solvent that fits the assay and include a matched vehicle control.
• Concentration planning: Calculate molar concentration from the reported molecular weight of 783.92 g/mol. Confirm the calculation against the lot documentation before preparing quantitative dose series.
• Comparative design: Keep peptide concentration, incubation time, temperature, buffer composition, and detection method constant when comparing the fragment with parent or truncated peptides.
• Interpretation: Separate direct cardiovascular endpoints from binding endpoints. A blood-pressure or aldosterone experiment requires its own validated biological readout.

The related article Angiotensin 1/2 (2-7): Applied Workflows in Blood Pressure Research emphasizes workflow use in cardiovascular models; this article extends that discussion by separating supplier specifications from peer-reviewed evidence and by defining cross-domain limitations.

The related article Applied Workflows with Angiotensin 1/2 (2-7) Peptide in RAS Research focuses on renin-angiotensin pathway applications; this article clarifies which claims are directly supported for the 2-7 fragment and which remain extrapolations from angiotensin II or other truncation products.

Conclusion & Outlook

Angiotensin 1/2 (2-7) is a defined six-residue angiotensin peptide fragment with documented composition, purity, solubility, and storage guidance. It offers a practical molecular probe for blood pressure regulation research and renin-angiotensin signaling pathway experiments. The 2025 spike-binding study adds a useful cross-domain observation, but it does not replace direct cardiovascular pharmacology or infection studies. The most informative next experiments are controlled comparisons that test fragment-specific receptor, vascular, aldosterone-related, or binding endpoints under explicitly reported conditions.